Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07348263 · ClinicalTrials.gov registry record

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

A clinical trial of Eosinophilic Fasciitis, sponsored by Meyer Children's Hospital IRCCS.

Recruiting
Registry status
20
Enrollment target
15
Study locations

NCT07348263: Recruiting study of Eosinophilic Fasciitis, sponsored by Meyer Children's Hospital IRCCS.

NCT07348263 is a study of Eosinophilic Fasciitis that is actively recruiting participants, run by Meyer Children's Hospital IRCCS. The registered enrollment target is 20 participants. The trial reports 15 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07348263, a study of Eosinophilic Fasciitis, is actively recruiting participants, sponsored by Meyer Children's Hospital IRCCS.

RECRUITING
Registry status
20 participants
Enrollment target
15
Study locations

Study Summary

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.

Primary Outcome

Describe the clinical and laboratory features at presentation and during follow-up, including the extent of skin involvement and extracutaneous manifestations, of patients diagnosed with JEF.

Conditions Studied

Study Locations (15)

Other

  • Children's Hospital Zagreb - Zagreb
  • Hamburger Zentrum für Kinder- und Jugendrheumatologie - - Hamburg
  • Ruth Rappaport Children's Hospital of Haifa - Haifa
  • IRCCS Giannina Gaslini, - Genova
  • Università di Udine - Udine
  • Iuliu Hatieganu University of Medicine and Pharmacy - Cluj-Napoca
  • University Children's Hospital - Ljubljana
  • Hospital Sant Joan de Déu, - Barcelona
  • Cerrahpasa Medical School, Istanbul University - Istanbul
  • Alder Hey Children's Hospital - Liverpool
  • Great North Children's Hospital, Newcastle Upon Tyne - Newcastle upon Tyne

Alabama

  • University of Alabama at Birmingham - Birmingham

New York

  • SUNY Upstate Pediatric Rheumatology - Syracuse

FI

  • Meyer Children's Hospital IRCCS - Florence

Stockholm County

  • Astrid Lindgren Children's Hospital - Solna

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-05-15
Est. Completion 2027-05-15
Meyer Children's Hospital IRCCS

6 total trials

What NCT07348263 shows while recruiting

NCT07348263 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.

The record links to 1 condition, with Eosinophilic Fasciitis appearing as the primary indexed condition, and to 0 interventions.

NCT07348263 lists 15 locations in 5 states (Other, Alabama, New York).

Frequently Asked Questions

What is clinical trial NCT07348263 about?

NCT07348263 is a clinical study titled "EFESO: Study on Juvenile Onset Eosinophilic Fasciitis". Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represent...

What is the current status of trial NCT07348263?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-05-15. Estimated completion is 2027-05-15.

What conditions does trial NCT07348263 study?

This clinical trial studies the following conditions: Eosinophilic Fasciitis.

Who is sponsoring clinical trial NCT07348263?

This trial is sponsored by Meyer Children's Hospital IRCCS, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07348263 being conducted?

This trial has 15 study locations across Alabama, New York, FI, Stockholm County. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07348263, the US trial registry maintained by the National Library of Medicine. NCT07348263 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.